Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 12 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (6)
P 1 (1)
P 2 (1)

Trial Status

Recruiting5
Completed4
Enrolling By Invitation2
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06936514Not ApplicableEnrolling By InvitationPrimary

Clinical Study on Deep Cervical Lymphatic Trunk Decompression Combined With Mid-Cervical Deep Lymph Node-External Jugular Vein Anastomosis for Alzheimer's Disease Treatment

NCT06965062Not ApplicableRecruiting

Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)

NCT07205003Recruiting

Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders

NCT07138677Not ApplicableRecruitingPrimary

Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial

NCT07027072Phase 2Recruiting

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

NCT07049341Not ApplicableEnrolling By InvitationPrimary

Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases

NCT06871839RecruitingPrimary

The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease

NCT06982170Not ApplicableCompleted

Co-design and Pilot Study in VR-based Physical Activity and Cognitive Training

NCT06965816CompletedPrimary

Using Neuroimaging to Early Diagnose Alzheimer's Disease Through Hippocampal Atrophy Assessment

NCT06828289Not Yet RecruitingPrimary

Rivastigmine Mini-Tablet for Alzheimer's Disease

NCT04983368Phase 1Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers

NCT06717971Not ApplicableCompletedPrimary

Utilization of Exergame Programs Among Elderly Residents in Rural Nursing Care Centers

Showing all 12 trials

Research Network

Activity Timeline